AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors

(The Yates Network) BIND Therapeutics clinical investigators presented Phase 1 results with BIND-014, its targeted docetaxel Accurin, in 28 heavily-pretreated patients with advanced or metastatic solid tumors. BIND-014 was shown to be generally safe and well-tolerated at the established maximum tolerated dose and showed encouraging signs of anti-tumor activity including one complete response, three partial responses and five patients with stable disease lasting at least four cycles.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news